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Abstract 
Background & Aims  
Characteristics of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) 
include susceptibility to infection, immune paresis, and monocyte dysfunction. 
MERTK, a receptor tyrosine kinase, is expressed by monocytes and macrophages 
and contributes to downregulation of innate immune responses. We investigated 
whether MERTK expression is altered on monocytes from patients with liver failure. 
Methods
We analyzed blood and liver samples collected from patients admitted to the liver 
intensive therapy unit at King’s College Hospital, London, from December 2012 
through July 2014. Patients had either ACLF (n=41), acute decompensation of 
cirrhosis without ACLF (n=9), cirrhosis without decompensation (n=17), or acute liver 
failure (n=23). We also analyzed samples from healthy individuals (controls, n=29). 
We used flow cytometry to determine level of innate immune function, and 
associated the findings with disease severity. We developed an assay to measure 
recruitment and migration of immune cells from the tissue parenchyma. 
Immunohistochemistry and confocal microscopy were used to determine levels of 
MERTK in bone marrow, liver, and lymph node tissues. We performed 
immunophenotype analyses and measured production of tumor necrosis factor and 
interleukin-6 and intracellular killing of Escherichia coli by monocytes and peritoneal 
macrophages incubated with lipopolysaccharide, with or without an inhibitor of 
MERTK (UNC569).
Results 
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Numbers of monocytes and macrophages that expressed MERTK were greatly 
increased the circulation, livers, and lymph nodes of patients with ACLF, compared 
to patients with stable cirrhosis and controls; MERTK expression (mean fluorescence 
intensity) correlated with severity of hepatic and extrahepatic disease and systemic 
inflammatory responses. Based on immunophenotype, migration, and functional 
analyses, MERTK-expressing monocytes migrate across the endothelia to localize 
into tissue sites and regional lymph nodes. Expression of MERTK reduced the 
response of cultured monocytes to lipopolysaccharide; addition of UNC569 restored 
production of inflammatory cytokines in response to lipopolysaccharide. 
Conclusions 
Patients with ACLF have increased numbers of immunoregulatory monocytes and 
macrophages that express MERTK and suppress the innate immune responses to 
microbes. Numbers of these cells correlate with disease severity and the 
inflammatory response. MERTK inhibitors restore production of inflammatory 
cytokines by immune cells from patients with ACLF, and might be developed to 
increase the innate immune response in these patients. 
Keywords 
ALF; SIRS; immune regulation; bacterial infection; 
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Introduction 
Patients with cirrhosis exhibit a marked susceptibility to infections, developing in 35% 
of hospitalised patients compared to 5-7% of the general population1. Furthermore, 
infection accounts for over 50% of admissions of cirrhotic patients to hospital and is 
the main precipitant for the rapid decompensation referred to as ‘acute-on-chronic’ 
liver failure (ACLF), which is associated with the development of multiple organ 
failure. Once established, ACLF carries a prohibitively high mortality rate and a 
significant burden on critical care services and healthcare resources2,3. Impaired 
peripheral immune responses to microbial challenges, termed immuneparesis, is 
postulated to be responsible for the development of secondary infections, and is an 
independent predictor of mortality in ACLF3. Despite advances in organ failure 
support, there are no targeted strategies to combat susceptibility to infection in 
patients with cirrhosis and ACLF.
Monocyte dysfunction in ACLF, characterised by low HLA-DR and attenuated pro-
inflammatory responses to microbial challenge, is associated with an adverse 
outcome and may account for the predisposition to infectious complications4,5. These 
observations in ACLF echo our recent findings of monocyte dysfunction and 
immuneparesis in acute liver failure (ALF)6. 
The MER receptor tyrosine kinase (MERTK) is a transmembrane protein of the TAM 
receptor family expressed on monocytes/macrophages and dendritic cells as well as 
epithelial cells and reproductive and neuronal tissues7,8. MERTK is activated by its 
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ligands Gas-6, Protein-S and Galectin-3, leading to receptor auto-phosphorylation 
and activation of the downstream signalling cascade8. 
MERTK is an important negative regulator of innate immune responses and plays a 
central role in resolution of inflammation through inhibition of pro-inflammatory 
responses to microbial challenge and promoting the clearance of apoptotic cells8,9. 
MERTK plays a pivotal role in regulation of monocyte inflammatory responses where 
its activation was shown to inhibit toll-like receptor (TLR) activation and cytokine-
receptor induced pro-inflammatory cytokine production through downstream 
activation of SOCS1/310. MERTK KO mice were hypersensitive to LPS and 
developed fatal TNF-? induced severe septic shock11. Moreover, elevated monocyte 
MERTK and Gas-6 levels have recently been reported in patients with septic shock 
with persistent expression associated with an adverse outcome12,13. 
In view of the recently described role of MERTK in suppressing innate immune 
responses, we sought to determine whether activation of this immune-regulatory 
pathway could account for monocyte/macrophage dysfunction, and establish its 
candidacy as an immunotherapeutic target to reduce susceptibility to infectious 
complications in patients with ACLF. 
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Methods 
Patients and sampling 
The study was approved by the King’s College Hospital Ethics Committee 
(12/LO/0167). Assent was obtained by the patients’ nominated next of kin if they 
were unable to give informed consent themselves. Between December 2012 and 
July 2014, 119 subjects were recruited to the study within 24 hours following 
admission to Liver Intensive Therapy Unit (LITU) or liver wards. Patients were 
categorised into different groups: ACLF (n=41), acute decompensation of cirrhosis 
with “no ACLF” (AD; n=9; according to the CLIF-SOFA classification previously 
described2), patients with cirrhosis with no evidence for acute decompensation 
(n=17), patients with acute liver failure (ALF; n=23) and healthy controls (HC; n=29). 
Cirrhosis was diagnosed by previous liver biopsy or clinical presentation with typical 
ultrasound or CT imaging. Exclusion criteria were: age <18 years, malignancy, 
immunosuppressive therapy other than corticosteroids, which were accepted if 
required for the treatment of autoimmune liver disease, alcoholic hepatitis or 
suspected relative adrenal insufficiency. 
Clinical, haematological, and biochemical parameters 
Full blood count, International normalized ratio (INR), liver and renal function tests, 
lactate, ammonia and clinical variables were prospectively entered into a database. 
The following disease severity scores were calculated: Child-Pugh, model of end-
stage liver disease (MELD), CLIF-SOFA2, North American Consortium for Study of 
End-stage Liver Disease (NACSELD)14, Acute Physiology and Chronic Health 
Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), 
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Sequential Organ Failure Assessment (SOFA) scores and infections were 
documented. 
Isolation of monocytes 
Monocytes were isolated using CD14-microbeads as described6 or sequential 
depletion using CD66abce-, CD56-microbeads and Pan-Monocyte Isolation Kit 
(Miltenyi Biotec, Germany). Purity of monocytes was assessed by flow-cytometry 
(Supplementary Material and Methods). 
Phenotyping of monocytes/macrophages and measurement of cytokine responses to 
lipopolysaccharide (LPS) 
Monoclonal antibodies against CD14, CD16, CD86, CD163, CD64, CCR2, CCR5, 
CCR7 (BD Biosciences, UK); HLA-DR, CD32, CX3CR1 (eBioscience, UK), hMer 
(R&D Systems, UK) were used to determine expression of phenotypic markers on 
monocytes from PBMC using flow-cytometry. Results expressed as % and/or mean 
fluorescence intensity (MFI). TNF-? and IL-6 levels following 4-6 hour incubation of 
PBMC or isolated monocytes with LPS were determined by flow-cytometry based 
intracellular staining as previously described6. Flow-cytometry data was analysed 
using Flowlogic software, Inivai Technologies, Australia. 
MERTK ligands and cytokines 
Gas-6 (Abnova, Taiwan), Protein-S (Abcam, UK) were measured in plasma- and 
Galectin-3 (eBioscience, UK) in serum-samples using ELISA. Plasma cytokines were 
measured using Meso Scale Discovery (MSD; Gaithersburg, USA) as previously 
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described6. TNF-? and IL-6 in cell culture supernatants were measured as previously 
described6. 
Immunohistochemistry and confocal microscopy 
Explanted liver tissue was obtained from patients undergoing orthotopic liver 
transplantation (OLT) for cirrhosis (n=6) or ACLF (n=6). Hepatic resection margins of 
colorectal malignancies (n=4) served as controls. Lymph nodes were obtained from 
5 patients undergoing OLT for decompensated cirrhosis and 5 controls (benign 
stricture of left hepatic duct [n=2]; giant hepatic cyst [n=1]). Exemplarily, one bone 
marrow trephine from an ACLF patient was included. Tissues were taken for 
diagnostic histological examination, formalin-fixed and paraffin-embedded. 
Immunohistochemistry/multispectral imaging6 and confocal microscopy were used to 
identify MERTK+CD68+, MERTK+CD163+, MERTK+Ki67+ cells (Supplementary 
materials and methods). 
Migration assay 
Human umbilical vein endothelial cells (HUVECs) were grown on collagen plugs in 
cell culture inserts and stimulated with TNF-? and IFN-?. Isolated monocytes were 
added on top of the HUVEC/collagen matrix. After 1.5h of incubation, non-migrated 
monocytes were harvested. Following 24h, reverse migrated monocytes were 
harvested by aspiration and subendothelial monocytes were recovered from the 
HUVEC/collagen matrix by incubation with collagenase. Monocyte populations were 
analysed using a CyAn flow-cytometer (Beckman Coulter, UK) (Supplementary 
material and methods). 
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In-vitro Inhibition of MERTK signalling pathway  
A small-molecule inhibitor of MERTK, UNC56915 (Calbiochem/Millipore, UK), was 
used. Isolated monocytes were pre-treated with UNC569 2μM. HLA-DR expression, 
TNF-?/IL-6 production were assessed by flow-cytometry. Apoptotic cells were 
stained by Annexin-V (BD Biosciences, UK) (Supplementary material and methods). 
Western Blot for p-Y-MERTK 
Isolated monocytes were starved for 4h and stimulated with 20nM Gas-6 (R&D 
systems, UK) for 10 min. Cells were harvested and lysed in RIPA buffer (Pierce, 
USA) containing phosphatase- and proteinase inhibitors. Proteins were separated on 
4-12% Bis-Tris NuPAGE gels (LifeTechnologies, UK) and transferred to PVDF 
membranes. Antibodies were obtained from Abcam, UK. (Supplementary material 
and methods). 
Statistical analysis 
Data are expressed as the median/interquartile range (IQR) unless otherwise 
specified. For data that did not follow a normal distribution, the significance of 
differences was tested using Mann-Whitney or Wilcoxon tests, Spearman’s 
correlation coefficients were calculated. Graphs were drawn using Prism 6.0c, 
GraphPad, USA.  
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Results 
Patient characteristics 
Compared to compensated cirrhotic patients, patients with ACLF showed 
significantly higher hepatic and extrahepatic composite organ failure scores (Child-
Pugh, MELD, CLIF-SOFA and NACSELD) and indices of systemic inflammatory 
responses: circulating white blood counts (WBC), monocytes, C-reactive protein 
(CRP) and SIRS score. As shown in Table S1, patients with acute decompensation 
and no ACLF (AD) had significantly lower disease severity scores (MELD, CLIF-
SOFA, NACSELD) compared to ACLF patients. Age did not differ between groups. 
The level of MER receptor tyrosine kinase (MERTK) expression on monocytes 
indicates disease severity, impaired anti-microbial responses and is associated with 
increased frequency of secondary infections in ACLF
As the MERTK signalling cascade is known to suppress pro-inflammatory responses 
to microbial challenge, we investigated MERTK expression on monocytes in ACLF. 
Whilst monocyte progenitors in the bone marrow were MERTK-negative (Figure 
S1B), MERTK-expressing circulating monocytes (MERTK+) were expanded in ACLF 
(n=34) compared to compensated cirrhotic patients (n=17) and HC (n=14) (median 
35.7% vs. 5.4/8.2%, both p<0.0001). Importantly, MERTK+ monocytes were also 
markedly expanded in ALF patients (n=23), a hepatic inflammatory pathology 
characterised by activation of SIRS responses and immuneparesis (Figure 1A-B). 
Elevated MERTK expression was detected on both CD16-negative (CD14+CD16-) 
and CD16-positive (CD14+CD16+) monocyte subsets with highest levels on 
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CD14+CD16+ cells (Figure S2). Expression of MERTK was independent of the 
underlying aetiology of chronic liver disease (CLD) (Figure S3A). 
Given the association between MERTK, disease severity and mortality in septic 
shock, we sought to determine whether MERTK expression on circulating monocytes 
could represent a biomarker of disease severity in ACLF. MERTK expression 
strongly correlated with the severity of hepatic and extra-hepatic disease severity- 
(Child-Pugh, MELD, CLIF-SOFA, NACSELD) and SIRS score (Figure 1C). Activation 
of SIRS responses, in the presence or absence of infection, was strongly associated 
with elevations in MERTK expression (Figure S4). 
In order to examine the relationship between MERTK expression and responses to 
microbial challenge, we determined the levels of MERTK, LPS-induced pro-
inflammatory cytokine secretion and intracellular killing of E.coli concomitantly in 
circulating monocytes. Compared to HC (n=10) and patients with stable cirrhosis 
(n=13), patients with AD (n=5) and ACLF (n=15) had significantly elevated 
expression of MERTK and attenuated levels of TNF-? and IL-6 following ex-vivo LPS 
challenge (Figure 1D-E). Moreover, LPS induced TNF-? and IL-6 production was 
negatively correlated to MERTK expression, MELD (Figure 1D), Child-Pugh (TNF-
?:r=-0.665/p<0.0001; IL-6:r=-0.559/p=0.002), CLIF-SOFA (TNF-?:r=-0.557/p=0.003; 
IL-6:r=-0.543/p=0.003), NACSELD (TNF-?:r=-0.564/p=0.002; IL-6:-0.459/p=0.016) 
and SIRS scores (TNF-?:r=-0.548/p=0.004; IL-6:r=-0.411/p=0.037). Oxidative burst 
responses to E.coli were preserved with no significant association with outcome 
(Figure S5). 
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In ACLF patients, culture-positive infectious complications occurred at a considerably 
higher frequency within the first 14 days following admission to LITU (34.1%) 
compared to AD patients without organ failure (11.1%; Table S1). Concomitantly 
ACLF patients had significantly higher monocyte MERTK-expression following 
admission to LITU when compared to AD and stable cirrhotic patients (ACLF 35.7% 
vs. AD 14.36% vs. cirrhosis 5.4%, p=0.0020/p<0.0001) (Figure 1E).  
We determined the temporal evolution of MERTK expression in patients with ACLF 
and its relationship to outcome. Overall, peak MERTK expression was detected on 
admission to LITU and subsequently decreased at day 3-5 following admission 
(n=21). When stratified according to survival, patients surviving the episode of ACLF 
had a significant reduction in MERTK expression whilst non-survivors did not (Figure 
1F). 
Phenotypic characterisation of MERTK-positive monocytes in ACLF 
In order to fully characterise circulating monocytes with impaired microbial responses 
in ACLF, we performed detailed immunophenotypic analyses examining the levels of 
activation (HLA-DR, CD86), Fc?-receptors (CD16, CD64, CD32), scavenger 
(CD163) and tissue-and lymph node homing markers (CCR2, CCR5, CX3CR1, 
CCR7) in the whole monocyte population. Circulating monocytes in ACLF (n=9) 
exhibited an anti-inflammatory phenotype (CD163highHLA-DRlowCD86low) with 
significant higher expression of tissue- and lymph node homing receptors 
(CCR5highCCR7high) and Fc?-receptors (CD32highCD64high) when compared to HC 
(n=9) (Figures 2A,S5). 
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Having established the relationship between the magnitude of MERTK expression 
and impaired microbial responses, we sought to further define the MERTK+ 
subpopulation of circulating monocytes expanded in patients with ACLF (Figure 2B-
C). Phenotypic analysis of the MERTK+ monocyte subpopulation (MERTK+; 36% 
[Figure 1A]) displayed significantly higher expression of CD16, HLA-DR, CD86, 
CD163 and CCR7 compared to MERTK-negative cells consistent with the phenotype 
of a more mature and differentiated monocyte lineage (Figure 2D). 
Elevated circulating ligands and constitutive receptor phosphorylation indicate 
activation of the MERTK signalling cascade in ACLF 
To identify ligands that activate the MERTK signalling pathway in ACLF, we 
measured circulatory levels of Gas-6, Galectin-3 and Protein-S. The plasma 
concentrations of all measured MERTK ligands were elevated in stable cirrhotic 
patients compared to HC. Moreover, Gas-6 and Galectin-3 were significantly higher 
in ACLF compared to HC (Figure 3A-C). Gas-6 and Galectin-3 levels did not 
correlate with MERTK-expression on monocytes and were independent of the 
underlying aetiology of CLD (Figure S3B-C). 
Ligand-induced receptor-auto-phosphorylation activates the MERTK cascade. To 
investigate whether higher surface expression of MERTK in ACLF reflects its 
activation, tyrosine-phosphorylation of MERTK upon Gas-6 stimulation was 
investigated on isolated monocytes ex-vivo. In comparison to healthy monocytes, 
which were phosphorylated in response to Gas-6, constitutive phosphorylation and 
unresponsiveness to Gas-6 stimulation was detected on monocytes from a 
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representative patient with ACLF indicating constitutive activation of the MERTK 
cascade (Figure 3D).  
Systemic microenvironmental factors in ACLF plasma induce a distinct MERTK-
positive monocyte phenotype 
As MERTK expression correlated with SIRS responses (Figures 1C,S4A-E), 
circulating inflammatory cytokines are likely to induce an expansion of MERTK+ 
monocytes in ACLF. Monocyte MERTK expression is modulated through activation 
of cytokine receptors by their ligands8 (e.g. IL-1016). In line with previous data4, we 
detect a distinct cytokine profile in patients with ACLF revealing high levels of TNF-?, 
IL-6, IL-10 and IL-8 in comparison to HC and cirrhotic patients respectively (Figure 
S6). Monocyte MERTK expression positively correlated with plasma levels of TNF-?, 
IL-6, IL-8 and IL-10 (Figure 3E). Corticosteroid-treated ACLF patients were 
characterised by significantly higher disease severity scores (MELD, CLIF-SOFA, 
both p<0.0001) and MERTK expression (Figure S4F). 
To assess the influence of the systemic inflammatory microenvironment on 
monocyte function in ACLF, we studied phenotype and function of healthy 
monocytes after conditioning in plasma derived from ACLF patients and healthy 
donors. Culture in the presence of ACLF plasma induced a distinct phenotype 
(MERTKhighCD163highHLA-DRlowCCR7high) resembling that described for monocytes 
ex-vivo with attenuated pro-inflammatory responses but higher oxidative burst 
responses to E.coli (Figures S5,S7-8). 
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MERTK-positive monocytes have reinforced potential to migrate across endothelial 
layers 
Following an infectious insult, circulating monocytes migrate across the endothelium 
into tissues where they differentiate into macrophages and promote anti-microbial 
responses17. Subsequently, they home to regional lymph nodes to elicit immune 
responses, or may return to the circulatory pool. We examined migratory 
characteristics of monocytes from ACLF patients across the endothelium into the 
subendothelial space and back across the endothelium (reverse-migration) using a 
novel in-vitro migration model. Reverse migration recapitulates the in-vivo pathway 
through which tissue monocytes/macrophages home to regional lymph nodes or re-
join the circulatory pool18.
A significantly higher percentage and number of MERTK+ monocytes underwent 
transendothelial migration and reverse migration when compared to HC (Figure 4A-
C). Cells that did not migrate were more often MERTK-. Analyses of reverse-
migrated monocytes revealed a MERTKhighCD163high phenotype (Figure 4C) similar 
to the MERTK+ subpopulation described in ACLF monocytes ex-vivo (Figure 2D). 
The in-vitro data imply that MERTK+ monocytes exhibit a preferential migratory 
pattern across endothelia, home into extracirculatory compartments and suppress 
tissue-specific immune responses.  
Endothelial dysfunction in cirrhosis19 may also promote the migration of 
monocytes/macrophages into tissues. We detect elevated levels of systemic- 
(sICAM-1 and sVCAM-1) and tissue (angiopoietin-2) specific-markers of endothelial 
dysfunction and leakage in patients with cirrhosis and ACLF (Figure S9). 
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ACLF is characterised by an expansion of immunoregulatory, MERTK-positive 
macrophages in tissue compartments and regional lymph nodes  
In view of our data revealing an expansion of MERTK+ monocytes in the circulation 
of patients with ACLF, that preferentially migrate across the endothelium, we 
examined these cells in the peritoneal cavity, livers and regional lymph nodes. 
The percentage of MERTK-expressing peritoneal macrophages (pM?) was 
significantly higher when compared to their circulatory counterparts (67.5% vs. 
24.8%, p=0.0079) (Figure 4D). The pM? phenotype was characterised by elevated 
expression of pro-resolution/anti-inflammatory and tissue- and lymph node homing 
markers: HLA-DRhighCD163highCX3CR1highCCR7high (Figure S10). Analysis of 
MERTK+ pM? subset shows a HLA-DRhighCD163highCCR7high phenotype that bears 
striking phenotypic and functional similarities to their circulatory counterparts 
described above (Figure 4E-F). 
Using multispectral analysis and confocal microscopy of liver explant tissue, we 
show a significant expansion of MERTKhighCD163high hepatic macrophages in ACLF 
patients when compared to cirrhotic patients without organ failure who underwent 
transplantation (n=6 each) and to pathological control tissue (n=4) (Figure 5A-B; 
Figure S1). MERTK+ macrophages were predominantly Ki-67 negative, suggesting 
they are recruited rather than resident in origin. 
Having documented a high expression of lymph node (LN) homing receptor, CCR7, 
on circulating monocytes and pM?, and, in view of the importance of LN 
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macrophages in filtering of tissue-derived pathogens and triggering anti-microbial 
responses, we evaluated MERTK expression in mesenteric lymph nodes (MLN) from 
patients with decompensated cirrhosis (n=5) and pathological controls (n=3). 
MERTK+/CD68+ MLN macrophages were markedly increased in decompensated 
cirrhotic patients compared to controls (185 vs. 90 cells/10HPF;p=0.0357). Strikingly, 
MERTK+ macrophages were distributed in both subcapsular and medullary (termed 
extra-follicular) regions of the LN (111 vs. 21 cells/10HPF;p=0.0357) (Figures 5C-D, 
S1), suggesting they enter both through lymphatics and high endothelial venules into 
areas where macrophages play a crucial role in triggering innate and adaptive anti-
microbial responses20. 
Inhibition of MERTK restores pro-inflammatory responses in ACLF  
As MERTK+ monocytes exhibited attenuated response to LPS challenge, inhibition 
of the MERTK signalling pathway may restore monocyte responses to microbial 
challenge. In a series of in-vitro experiments, ACLF (MERTK+ 69.9%) and HC-
conditioned monocytes (MERTK+ 51.6%) were cultured in the presence and 
absence of MERTK-inhibitor UNC569 (Figure 6A). Culture of monocytes with 
UNC569 (2μM) for 24h significantly up-regulated activation marker HLA-DR in ACLF 
(n=10) but not HC (n=6) (Figure 6B). In ACLF, UNC569 (2 μM) treatment for 6h led 
to a significant increase in both LPS-induced TNF-? and IL-6 production but not 
intracellular killing of E.coli (Figures 6C-D,S5; n=4 each). There was no increase in 
apoptotic cells in the UNC569 treated ACLF monocytes in-vitro (1.3 vs. 1.2%, 
p=0.968). 
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Discussion 
The marked expansion of an immunoregulatory, MERTK-expressing 
monocyte/macrophage population is a novel finding in the pathogenesis of 
immuneparesis in ACLF. In particular, the magnitude of MERTK expression on 
circulating monocytes strongly correlated with suppression of innate immune 
responses to microbial challenge, suggesting that MERTK may serve as a marker of 
innate immune dysfunction in ACLF. Further analyses reveal that these monocytes 
express the anti-inflammatory (CD163highHLA-DRlow) phenotype that has been 
extensively described in other hepatic4-6 and systemic inflammatory pathologies21
where there is immuneparesis and susceptibility to infectious complications. 
The biological relevance of this immunoregulatory, MERTK+ monocyte phenotype in 
ACLF is highlighted through its strong relationship with hepatic and extrahepatic 
disease severity scores (Child-Pugh, MELD, CLIF-SOFA, NACSELD) and with the 
magnitude of SIRS response, irrespective of the presence or absence of infection. 
This significant finding corroborates previous reports identifying the importance of 
SIRS during the evolution of ACLF4.  
Immune profiling of circulating monocytes in ACLF reveals that the major defect in 
innate responses is the impairment of pro-inflammatory responses to microbial 
challenge. These findings are corroborated by a number of previous publications by 
us and others4,5,22. However, we did not detect defects in ex-vivo bacterial killing, as 
recently reported in patients with decompensated cirrhosis (AD)23. These findings 
are perhaps not surprising in view of the fact that monocytes exhibit marked 
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functional plasticity during a given inflammatory insult. Our findings could be 
explained by the fact that activation of SIRS responses, that define the transition 
from AD to ACLF, enhance the production of reactive oxygen species and the 
bacterial killing ability of monocytes24. Further studies are needed to dissect defects 
in innate immune dysfunction during the clinical evolution of disease. 
We moreover identified a higher frequency of infectious complications in those 
patients who had higher MERTK expression and severity of organ failure. To our 
knowledge, this is the first description of a biomarker linking and possibly predicting 
disease severity and immuneparesis. Large prospective studies are warranted to 
assess its utility in patients with ACLF. 
Our data reveal a marked expansion of MERTK+ monocytes/macrophages in tissue 
compartments (e.g. peritoneum, liver) and in mesenteric lymph nodes, where 
monocytes/macrophages are recruited via afferent lymphatics draining regional 
tissue compartments. Characterisation of peritoneal MERTK+ macrophages reveals 
striking phenotypic (HLA-DRhighCD163high) and functional (attenuated pro-
inflammatory responses) similarities with their circulatory counterparts. Analyses of 
ACLF liver tissue also show a macrophage rich infiltrate bearing a 
MERTKhighCD163high phenotype particularly within the hepatic sinusoids. These data 
suggest that MERTK+ monocytes/macrophages accumulate in different tissue 
compartments in ACLF. 
We reveal that a high proportion of MERTK-bearing monocytes and peritoneal 
macrophages express tissue and lymph node homing receptors. Moreover, we show 
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that these monocytes have enhanced migratory capabilities, and are able to migrate 
efficiently across endothelia from blood to tissue and then out of tissue bearing the 
characteristic MERTKhighCD163high phenotype. Apart from the enhanced migratory 
capabilities of MERTK+ monocytes, endothelial dysfunction in CLD19 and organ 
failure25 might further facilitate their tissue homing capabilities. In line with this 
theory, angiopoietin-2, a marker of endothelial “leakage” in cirrhosis19 was highly 
expressed in hepatic endothelia in cirrhosis and ACLF patients. 
The data suggest that a dynamic circulatory pathway exists where MERTK+ cells 
traffick from tissue sites to regional lymph nodes and back to the circulation. In 
support of this theory, we observed a striking increase in the number of subcapsular 
sinus and medullary cord (extra follicular) macrophages expressing MERTK in the 
mesenteric lymph nodes from patients with decompensated cirrhosis. The low 
number of resident, proliferating monocytes/macrophages support that they are 
predominantly recruited from the circulatory monocyte pool. These macrophages 
serve to “filter” tissue and lymph borne pathogens, preventing their systemic 
translocation and priming innate and adaptive immune responses26. Taken together, 
we hypothesise that the increase in MERTK+ macrophages in mesenteric lymph 
nodes is of major pathogenic significance contributing to suppression of innate 
immune responses to microbial challenge in patients with ACLF. 
The strong correlation of MERTK expression with SIRS and circulatory cytokines on 
the one hand and with liver disease severity on the other hand, supports the notion 
that both systemic and intrahepatic inflammatory events in ACLF mould monocytes 
towards a MERTK+ phenotype. Our data demonstrate that monocytes acquire 
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MERTK expression once they exit the bone marrow and are exposed to circulating 
inflammatory mediators in ACLF plasma. Circulatory inflammatory factors favouring 
monocyte differentiation towards a MERTK+ phenotype include MERTK ligands, 
cytokines and corticosteroids27. We observed elevated levels of MERTK ligands 
(Gas-6, galectin-3) and inflammatory cytokines in patients with cirrhosis and ACLF, 
suggesting these mediators may modulate monocyte MERTK expression. The 
positive correlation of MERTK expression with TNF-?, IL-6 and IL-10 might indicate 
a role for these cytokines in inducing MERTK in ACLF. Cytokines have been 
reported to induce TAM receptor activation10, in particular IL-10 has previously been 
shown to up-regulate MERTK expression16. ACLF patients treated with 
corticosteroids had significantly higher disease severity scores and MERTK 
expression. The effect of inflammatory mediators and steroid treatment on MERTK 
expression alone cannot be distinguished in this ACLF cohort.  
Data from patients with ALF revealing high disease severity, SIRS and high MERTK 
but low steroid treatment rate suggest that circulating inflammatory mediators (e.g. 
IL-10) are likely to be the main triggers for MERTK expression. However, further 
work is necessary to dissect how different mediators modulate MERTK expression 
on monocytes in ACLF. 
During acute liver injury, hepatocyte death triggers an expansion of resolution 
macrophages in the liver6. The magnitude of hepatocellular apoptosis has previously 
been linked to disease severity in ACLF28. Resolution of tissue inflammation requires 
activation of MERTK-dependant pathways, triggered by the surface expression of 
phosphatidylserine on apoptotic cells9. Consequently, activation of MERTK-mediated 
uptake of apoptotic cells might contribute to the expansion of the MERTK+ 
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macrophage population we describe in ACLF. The role of hepatocyte death as a 
driver of MERTK expression is corroborated by its strong correlation with liver-
specific disease severity scores. Equally, apoptosis of parenchymal cells in other 
epithelial beds (e.g. kidney29) may also promote MERTK+ monocytes/macrophages 
during the evolution of organ failure in ACLF.  
In Figure 7, we provide a mechanistic explanation to account for the expansion of 
MERTK+ monocyte/macrophages in the circulation and tissue compartments of 
patients with ACLF. Here, we propose that systemic inflammatory mediators and 
repeated cycles of migration in and out of inflamed tissues, facilitated by endothelial 
dysfunction, results in up-regulation of MERTK and suppression of innate immune 
responses. 
Immuneparesis had previously been linked to secondary infections, which are the 
major cause of death in patients with ACLF3,4. Current treatment involves 
prophylactic and targeted antibiotic agents, which contribute to the emergence of 
antimicrobial resistance and often do not prevent recurrent infections. Strategies 
enhancing innate immune responses might be beneficial in preventing secondary 
infection and improving outcome. Having identified an immunoregulatory monocyte 
population, we evaluated its candidacy as a future immunotherapeutic target. 
MERTK negatively regulates pro-inflammatory-responses to microbial challenge14
and therefore represents a promising target. This is supported by our experiments 
showing that MERTK inhibition in ACLF monocytes in-vitro leads to up-regulation of 
their activation marker, HLA-DR, and to enhanced response to microbial challenge 
and is consistent with recent reports where inhibition of MERTK restored LPS-
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induced pro-inflammatory response in a STAT1-SOCS1/3-NF?B dependant 
manner30. Absence of MERTK in microenvironmental leucocytes stimulated anti-
tumour immune responses in mice31. In humans, MERTK inhibitors are being 
evaluated for the treatment of cancer such as glioblastoma32 and might be 
accessible in ACLF. 
In view of our findings, we hypothesise that an immunotherapeutic strategy, aimed at 
inhibiting MERTK and restoring monocyte responses to bacterial challenge, is likely 
to be of clinical benefit if instituted early in disease evolution in order to prevent 
attendant secondary infections. The dynamic evolution of innate immune defects 
exemplifies the importance of immune profiling before embarking on 
immunostimulatory therapeutic strategies. Further studies are warranted to identify 
the optimal strategy aimed at boosting innate immune response in ACLF. 
In conclusion, our data reveal a marked expansion of MERTK expressing, 
immunoregulatory monocytes/macrophages in the circulation and in tissues in 
patients with ACLF that strongly correlates with indices of liver disease severity and 
activation of SIRS responses. Functionally MERTK+ cells have attenuated response 
to microbial challenge, which might explain predisposition to secondary infection in 
ACLF. Furthermore, we have identified a mechanism that is key to 
monocyte/macrophage dysregulation and immuneparesis in ACLF and provides a 
novel immunotherapeutic target aimed at restoring innate immune responses to 
microbial challenge and reducing susceptibility to infections. 
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Figure legends 
Figure 1. MERTK expression and innate responses in circulatory monocytes in 
ACLF A. MERTK expressing monocytes (%CD14+ cells) in ACLF (n=34), ALF 
(n=23), cirrhosis (n=17) and healthy controls (n=14). B. Representative FACS-plot to 
determine MERTK expressing CD14+ monocytes. C. Correlation of MERTK 
expression with Child-Pugh, MELD, CLIF-SOFA, NACSELD, SIRS scores. D. LPS-
induced TNF-?/IL-6-production in stable cirrhosis, AD, ACLF and correlation with 
MERTK expression and MELD. E. MERTK expression in cirrhosis (n=17), AD (n=7), 
ACLF (n=34) (%CD14+ cells). F. Sequential MERTK expression (admission; day 3-5 
following admission for ACLF). 
Figure 2. Phenotypic characterisation of circulating monocytes in ACLF A. 
Immunophenotyping of monocytes in ACLF compared to healthy controls reveals a 
MERTKhigh/HLA-DRlow/CD163high/CCR5high/CCR7high phenotype. B. Representative 
FACS-plot to assess the phenotype of the MERTK+ subpopulation. C. MERTK+ 
monocytes in ACLF (n=30), cirrhosis (n=8) and healthy controls (n=14). D. The 
immunophenotype of MERTK+ monocytes in ACLF is HLA-
DRhigh/CD16high/CD163high/CCR7high.
Figure 3. Activation of the MERTK signalling cascade in ACLF. A-C. Elevation of 
MERTK ligands Gas-6 (pg/ml), Galectin-3 (ng/ml) and Protein-S (μg/ml) in ACLF 
(n=35), cirrhosis (n=11) and healthy controls (n=15). D. Immunoblotting for phospho-
Y-MERTK in response to Gas-6-stimulation (20nM) on isolated monocytes from a 
healthy control and an ACLF patient ex-vivo. E. Correlation of plasma cytokine levels 
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of patients with cirrhosis and ACLF with monocyte MERTK expression (n=60). ** 
p<0.01. 
Figure 4. MERTK+ monocytes preferentially migrate across endothelia in an in-
vitro model and are expanded in the peritoneal cavity ex-vivo. A.  MERTK+ 
monocytes conditioned in ACLF- and healthy plasma. B. Percent of migrated 
(subendothelial) MERTK+ monocytes in ACLF- (n=5) vs. healthy controls (n=4). C. 
Left: Number of non-migrated, subendothelial and reverse migrated MERTK+ and 
MERTK- cells/?l.; Right: %CD14+ monocytes expressing CD163, HLA-DR in 
different in-vitro compartments. D. Representative FACS-plot to assess phenotype of 
MERTK+ vs. MERTK- peritoneal macrophages (pM?) (left) in patients with cirrhosis 
and ascites. %MERTK+ vs. MERTK- subpopulations in circulatory monocytes and 
pM? (right). E. Immunophenotype of MERTK+ and MERTK- pM?. F. LPS- induced 
TNF-?/IL-6-production in pM?.  *, p<0.05, **p<0.01. 
Figure 5. MERTK expressing macrophages accumulate in the liver and in 
mesenteric lymph nodes in patients with ACLF and decompensated cirrhosis. 
A. Immunostaining for MERTK+ and MERTK+/CD163+ macrophages in pathological 
control, cirrhotic and ACLF liver tissue(200x), (Inset: composite pseudo-fluorescent 
images from multispectral analysis[400x]). Right panel: Representative confocal 
image of double-epitope fluorescent immunostaining for 
CD68(green)/MERTK(red)/co-localisation(yellow) on ACLF liver tissue confirming 
MERTK expression in macrophages(400x). B. Enumeration of CD163+/MERTK+ 
macrophages in hepatic plates of control (n=4), cirrhosis (n=6), and ACLF (n=6) liver 
tissue (cells/10 high power fields [HPF]). C. Immunostaining for MERTK+ and 
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MERTK+/CD68+ macrophages in follicular and non-follicular areas of regional lymph 
nodes from controls (n=3) and decompensated cirrhosis (n=5) (200×) (Insets: 
composite pseudo-fluorescent images from multispectral analysis[400x]). Right 
panels: Confocal images of double-epitope fluorescent immunostaining for 
CD68(green)/MERTK(red)/co-localisation(yellow) in non-follicular lymph nodes areas 
confirming MERTK expression in CD68+ macrophages(400×). D. Number 
(cells/10HPF; left and middle panels) and % of MERTK+ cells (right panel) in lymph 
nodes follicular and non-follicular areas. 
Figure 6. MERTK-inhibition by UNC569 improves LPS-response to microbial 
challenge in ACLF monocytes in-vitro. A. Expansion of MERTK+ monocytes after 
conditioning of healthy monocytes in ACLF- compared to healthy plasma (%CD14+ 
cells). Graph shows mean+/-SEM. B. Expression of HLA-DR after UNC569(2μM) 
treatment in-vitro for 24h. ACLF n=10, healthy n=6. C-D. LPS-induced TNF-? and IL-
6 production after UNC569(2μM) treatment for 6h. 
Figure 7. Mechanistic model explaining the expansion of MERTK-positive, 
immunoregulatory monocytes/macrophages in ACLF as a multisystem 
disorder. Circulating monocytes derived from the bone marrow do not express 
MERTK (MERTK-; green) (1). In the circulatory microenvironment in ACLF, with high 
levels of IL-10, IL-6, TNF-? and Gas-6, monocytes differentiate and express MERTK 
(MERTK+; orange) (2). MERTK+ monocytes express tissue homing receptors and 
preferentially migrate across endothelia into sites of inflammation/infection (e.g. liver, 
peritoneum [3]). Predominantly in the liver and extrahepatic sites of inflammation, 
infiltrated MERTK+ monocytes interact with phosphatidylserine on apoptotic cells, 
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induce their clearance and further up-regulation of MERTK (4). Tissue 
monocytes/macrophages are phenotypically MERTKhigh/CD163high/HLA-DRhigh, 
functionally endotoxin tolerant (red) and migrate to regional lymph nodes (5). 
MERTK+ monocytes/macrophages with enhanced migratory potential return to the 
circulation (reverse migration [6]). Expansion of MERTKhigh/CD163high/HLA-DRhigh, 
immunoregulatory monocytes in ACLF (red) occurs in inflamed tissues, lymph nodes 
and the circulation. 
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Supplementary Material and Methods 
Isolation of monocytes 
Monocytes were isolated using CD14-microbeads as previously described1. To 
increase the purity of monocytes for protein extraction and Western blotting, we 
applied a sequence of depletion using CD66abce-, CD56-microbeads and the Pan 
Monocyte Isolation Kit (Miltenyi Biotec, Germany) according to manufacturer’s 
instructions. Purity of monocyte isolation was assessed by flow-cytometry. 
Purity of monocytes following isolation using a sequence of negative selection.
Representative dot plot showing gated monocytes on the forward- and side scatter 
profile (left). The purity of monocytes including all different subsets was routinely 
characterised by the expression of CD14 using APC-H7 and CD16 using PerCP-
Cy5.5 (a purity of 97% in this representative isolation) (right). SSC: side scatter; 
FSC: forward scatter. 
Migration assay 
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Cell culture inserts (0.4 ?m pore size; Merck Millipore, Germany) were placed in 24-
well plates (Corning, USA) containing 700 ?l human endothelial-SFM media 
supplemented with 0.1% BSA (Life Technologies, UK). A collagen plug was then 
formed in the insert using bovine collagen I (3 mg/ml) prepared with MEM and 
NaOH, and overlayered with 50 ?l human fibronectin (50 ?g/ml; Life Technologies, 
UK).  The solutions were then left to equilibrate for 2 h at 37 °C, 5% CO 2.  
Following a further 4-6 h incubation with fresh SFM media, 5×104 human umbilical 
vein endothelial cells (HUVECs) (prepared as described in Jaffe et al.2), in EBM-2™ 
endothelial medium (Lonza, Switzerland), were seeded on top of each collagen plug. 
HUVECs were grown to confluence for 24 h and then were stimulated with fresh 
EBM-2™ medium containing TNF-? and IFN-? (both 10 ng/ml) (R&D Systems) for a 
further 24 h at 37 °C, 5% CO 2.  
Next, CD14+ microbead-isolated monocytes (Miltenyi Biotec, UK) were pre-
conditioned for 24 h with ACLF or HC plasma (20% plasma/complete medium) in 24-
well plates. Monocytes, 2x106 in SFM medium, were added on top of the 
HUVEC/collagen matrix and incubated at 37 °C, 5% CO 2. After 1.5 h, non-migrated 
monocytes were harvested by washing thoroughly the top of the well with SFM 
medium, before fresh (2.5% FBS) SFM medium was added on top. Following a 
further 24 h incubation at 37 °C, 5% CO 2, reverse migrated monocytes were 
harvested by careful aspiration. Subendothelial monocytes were recovered from the 
HUVEC/collagen matrix by incubation with collagenase solution (Sigma-Aldrich, UK) 
for 45 min 37 °C, 5% CO 2. The monocyte populations were then washed with PBS 
and analysed using a CyAn flow cytometer (Beckman Coulter, UK). 
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Simplified diagram of the in-vitro migration assay.  Endothelial cells are plated on a 
collagen plug and stimulated with TNF-?/IFN-? to form a confluent monolayer. 
Monocytes (2x106/well) are added on top of the collages plug. Non-migrated 
monocytes are harvested at 1.5 hours.  Following a 24 h culture period, reverse 
migrated monocytes are harvested and subendothelial monocytes are obtained 
following collagenase digestion. 
Monocyte oxidative burst activity against E.coli 
Monocyte intracellular killing of E.coli by oxidative burst was assed using Phagoburst 
kit (Glycotope, Heidelberg, Germany) following the manufacturer’s instructions. 
Heparinised whole blood from patients with stable cirrhosis, ACLF and healthy 
controls was processed within maximal 4h after phlebotomy. 100μl of whole blood 
was incubated with 20μl of E. coli particles for 20 min. at 37°C. Rhodamine was used 
as a fluorochrome. CD14 positive cells were stained using APC-H7 labeled CD14 
antibody for 20 min. The burst activity was immediately assessed by flow cytometry. 
Inhibition of MERTK in monocytes in-vitro 
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For the inhibition of MERTK in-vitro we used the small molecule inhibitor UNC5693
(Calbiochem Millipore, UK). Monocytes were isolated using CD14 microbeads, purity 
of monocytes was >90%. Cells were seeded on 48-well plates (500’000 cells/well) 
and cultured in X-vivo 10 medium (Lonza, Switzerland) containing 25% of plasma 
from different ACLF patients and HC respectively in a 37°C, 5% CO 2 environment for 
16h. Phenotypic analysis using flow-cytometry was performed on these monocytes 
grown in different donors’ plasma. 
Cells were treated with UNC569 2 μM or DMSO respectively for 24h prior to 
phenotypic analysis of HLA-DR expression by flow-cytometry. 
For analysis of cytokine production, cells were pre-treated with UNC569 2 μM or 
DMSO respectively for 2h prior to stimulation with LPS 100 ng/ml for subsequent 4h. 
TNF-?/ IL-6 production was assessed by flow-cytometry as previously described1. 
Apoptotic cells were stained by Annexin-V (BD Biosciences, UK). UNC569 2 μM had 
been identified to influence cytokine production as well as HLA-DR expression more 
potently compared to lower- (1 μM) and higher doses (5 and 10 μM) without 
increasing the rate of apoptosis to >7%. 
To investigate the effect of UNC569 on oxidative burst activity, cells were pre-treated 
with UNC569 2 μM or DMSO respectively for 2h prior to stimulation with E. coli 
particles (cell to particle ratio: 250’000 monocytes to 20 μl E. coli) for 20 min at 37°C. 
Rhodamine was used as a fluorochrome (20 μl per 250’000 cells). CD14 positive 
cells were stained using APC-H7 labeled CD14 antibody for 20 min. The burst 
activity was immediately assessed by flow cytometry. 
Western Blot for p-Y-MERTK 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MERTK in ACLF – Supplementary Material& Methods   
5
For protein extraction monocytes isolation from freshly extracted PBMCs was done  
using the sequential negative selection described above. Purity of monocytes was 
>95%. Cells were grown on 24-well plates (2x106 cells/well) in RPMI-1640 medium 
(Sigma-Aldrich, St. Louis, USA) and starved for 4h. Cells were stimulated with 20 nM 
human recombinant Gas-6 (R&D systems, UK) or dH20 respectively for 10 min. The 
dose was selected in correspondence to the highest plasma level measured in 
patients with ACLF previously. Cells were harvested on ice and washed in ice-cold 
PBS containing 1 mmol/l vanadate, centrifuged at 14000 rpm for 5 min. The pellet 
was lysed in 60μl RIPA buffer (Pierce, Rockford, USA) containing 1 mmol/l 
vanadate, 1:100 phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich, St. Louis, 
USA) and 1:25 proteinase inhibitor (Roche, Basel, Switzerland) on ice for 30 min. 
and centrifuged at 14000 rpm for 5 min. Protein concentrations were measured using 
Bradford reagent (BioRad, Hercules, USA). Samples were denaturated in 4x LDS 
Sample loading buffer/ 4% ?-mercaptoethanol for 5 min. at 100°C. Samples were 
loaded on a 4-12% NuPAGE Bis-Tris Protein Gel (LifeTechnologies, Paisley, UK), 
transferred to a PVDF membrane using wet-transfer method (20% methanol) and 
blocked with 5% milk in PBS-Tween-20 (PBS-T). Antibodies against phospho-Y-
MERTK, MERTK and ?-actin were obtained from Abcam (Cambridge, UK). For 
detection 20XLumiGlow/Peroxidase was used (Cell-Signaling, Danvers, USA). 
Assessment of sICAM-1 and sVCAM-1 
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Human soluble intercellular adhesion molecule-1 (hs ICAM-1; ng/ml) and human 
soluble vascular cell adhesion molecule 1 (hs VCAM-1; ng/ml) were measured by 
enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s 
instructions (eBioscience, Hatfield, UK). 
Immunohistochemistry and confocal microscopy 
A. MERTK enzymatic immunohistochemistry 
Formalin-fixed and paraffin-embedded (FFPE) tissue was cut at 4 ?m using a Leica 
RM2235 rotary microtome (Leica Biosystems, UK) and picked up on poly-l-lysine 
coated slides which were manually stained using a rabbit monoclonal anti-MERTK 
primary antibody (catalog number ab52968, Abcam, UK; dilution 1:300). Slides were 
dewaxed in xylene, rehydrated, subjected to heat-induced epitope retrieval (HIER) 
using sodium citrate buffer, pH 6, for 20 minutes, and allowed to cool, followed by 1 
hour incubation at room temperature with the primary antibody. The signal was 
detected using the EnVisionTM G/2 Doublestain System, Rabbit/Mouse 
(DAB+/Permanent Red) (product number K536111-2, Dako, UK), and visualized with 
the Vector VIP peroxidase kit (catalog number SH-600, Vector Laboratories, UK). 
The slides were then dehydrated with alcohol, cleared with xylene and cover slipped 
with DPX (Leica Biosystems, UK) after hematoxylin counterstaining. Images were 
captured and processed with a Nikon Eclipse E600 microscope using the Nuance™ 
3.0.2 (PerkinElmer, UK) multispectral imaging technology. Cells were counted using 
ImageJ software (Bethesda, USA) on 10 random high power fields (HPF). 
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Immunostains were analysed by a liver histopathologist (A.Q.) who was blinded to 
clinical data. 
B. MERTK-CD68 enzymatic immunohistochemistry 
FFPE tissue was cut at 4 ?m using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-l-lysine coated slides which were manually 
stained using a rabbit monoclonal anti-MERTK primary antibody (catalog number 
ab52968, Abcam, UK; dilution 1:300) and a mouse monoclonal anti-CD68 antibody 
(product number M0876, Dako, UK; dilution 1:50). Slides were dewaxed in xylene, 
rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate 
buffer, pH 6, for 20 minutes, and allowed to cool, followed by 1 hour incubation at 
room temperature with the anti-CD68 antibody. The signal was detected using the 
EnVisionTM G/2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) 
(product number K536111-2, Dako, UK), with 3,3’-diaminobenzidine (DAB) for 
visualization. The slides were then incubated for 1 hour at room temperature with the 
anti-MERTK antibody, and the second signal was detected using the same detection 
kit but with the Vector VIP peroxidase kit (catalog number SH-600, Vector 
Laboratories, UK) for visualization. Slides were then dehydrated with alcohol, cleared 
with xylene and cover slipped with DPX (Leica Biosystems, UK) after hematoxylin 
counterstaining. Images were captured and processed using the same microscope 
and software as described above. 
C. MERTK-CD163 enzymatic immunohistochemistry 
FFPE tissue was cut at 4 ?m using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-l-lysine coated slides which were manually 
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stained using a rabbit monoclonal anti-MERTK primary antibody (catalog number 
ab52968, Abcam, UK; dilution 1:300) and a mouse monoclonal anti-CD163 antibody 
(catalog number sc-33715, Santa Cruz Biotechnology, Germany; dilution 1:50). 
Slides were dewaxed in xylene, rehydrated, subjected to heat-induced epitope 
retrieval (HIER) using sodium citrate buffer, pH 6, for 20 minutes, and allowed to 
cool, followed by 1 hour incubation at room temperature with the anti-MERTK 
antibody. The signal was detected using the EnVisionTM G/2 Doublestain System, 
Rabbit/Mouse (DAB+/Permanent Red) (product number K536111-2, Dako, UK), with 
DAB for visualization. Slides were then incubated overnight at 4°C with the anti-
CD163 antibody. The second signal was detected using the Novolink Polymer 
Detection kit (code RE7200-K, Novocastra, UK) with the Vector VIP peroxidase kit 
(catalog number SH-600, Vector Laboratories, UK) for visualization. Slides were then 
dehydrated with alcohol, cleared with xylene and cover slipped with DPX (Leica 
Biosystems, UK) after hematoxylin counterstaining. Images were captured and 
processed using the same microscope and software as previously described. 
D. MERTK-CD68 fluorescent immunohistochemistry 
FFPE tissue was cut at 4 ?m using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-l-lysine coated slides which were manually 
stained using a rabbit monoclonal anti-MERTK primary antibody (catalog number 
ab52968, Abcam, UK; dilution 1:100) and a mouse monoclonal anti-CD68 antibody 
(product number M0876, Dako; UK, dilution 1:100). Slides were dewaxed in xylene, 
rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate 
buffer, pH 6, for 20 minutes, and allowed to cool, followed by an overnight incubation 
at 4°C with a cocktail of primary antibodies. The s econd day the slides were 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MERTK in ACLF – Supplementary Material& Methods   
9
incubated again overnight in the same conditions with a biotinylated goat-anti rabbit 
secondary antibody (product number E043201-8, Dako, UK; dilution 1:400) together 
with an Alexa 488 goat anti-mouse secondary antibody (catalog number A11029, 
Life Technologies, UK; dilution 1:400). This was followed by a third overnight 
incubation at 4°C with Alexa Fluor 548-conjugated s treptavidin (catalog number S-
32356, Life Technologies, UK; dilution 1:300). All slides were counterstained with 
4?,6-diamidino-2-phenylindole (DAPI) (catalog number D1306, Life Technologies, 
UK), cover slipped using a fluorescence mounting medium (catalog number 
S302380-2, Life Technologies, UK) and imaged using a confocal microscope (Zeiss, 
UK). 
E. MERTK-Ki67 enzymatic immunohistochemistry 
FFPE tissue was cut at 4 ?m using the same rotary microtome as previously 
specified and picked up on poly-l-lysine coated slides which were manually stained 
using a rabbit monoclonal anti-MERTK primary antibody (catalog number ab52968, 
Abcam, UK; dilution 1:300) and a mouse monoclonal anti-Ki67 antibody (product 
number M7240, Dako, UK; dilution 1:50). Slides were dewaxed in xylene, 
rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate 
buffer, pH 9, for 20 minutes, and allowed to cool, followed by 1 hour incubation at 
room temperature with the anti-Ki67 antibody. The signal was detected using the 
EnVisionTM G/2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) 
(product number K536111-2, Dako, UK), with 3,3’-diaminobenzidine (DAB) for 
visualization. The slides were then incubated for 1 hour at room temperature with the 
anti-MERTK antibody, and the second signal was detected using the same detection 
kit but with the Vector VIP peroxidase kit (catalog number SH-600, Vector 
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Laboratories, UK) for visualization. Slides were then dehydrated with alcohol, cleared 
with xylene and cover slipped with DPX (Leica Biosystems, UK) after hematoxylin 
counterstaining. Images were captured and processed using the same microscope 
and software as described above. 
F. MERTK-Ki67 fluorescent immunohistochemistry 
FFPE tissue was cut at 4 ?m using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-l-lysine coated slides which were manually 
stained using a rabbit monoclonal anti-MERTK primary antibody (catalog number 
ab52968, Abcam, UK; dilution 1:50) and a mouse monoclonal anti-Ki67 antibody 
(product number M7240, Dako; UK, dilution 1:25). Slides were dewaxed in xylene, 
rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate 
buffer, pH 9, for 20 minutes, and allowed to cool, followed by 1.5 hour incubation at 
room temperature with a cocktail of primary antibodies. Then the slides were 
incubated overnight at 4°C with a mixture of Alexa 488 goat anti-mouse (catalog 
number A11029, Life Technologies, UK; dilution 1:400) and Alexa Fluor 594 (catalog 
number A11037, Life Technologies, UK; dilution 1:400). All slides were 
counterstained with 4?,6-diamidino-2-phenylindole (DAPI) (catalog number D1306, 
Life Technologies, UK), cover slipped using a fluorescence mounting medium 
(catalog number S302380-2, Life Technologies, UK) and imaged using a Leica DMR 
microscope equipped with a Leica DFC300 FX camera using the Leica Application 
Suite V3.2.0 software (Leica Microsystems, Newcastle Upon Tyne, UK). The images 
taken for each channel were merged using the ImageJ software (Bethesda, 
Maryland, USA). 
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G. Assessing MERTK-expression in macrophages using Nuance multispectral 
imaging technology and confocal microscopy. 
Double epitope enzymatic immunohistochemistry (MERTK-CD68 and MERTK-
CD163) was suggestive of co-localisation of MERTK with CD68+ and CD163+in h-
m?. Distinguishing between brown and purple and unmixing these co-localised 
chromagens are not feasible with an RGB camera as it only uses 3 channels. So a 
multispectral approach was used on these stains, as well as the MerTK-Ki67 double 
epitope enzymatic immunohistochemistry. Nuance camera takes several images 
over different wavelengths, thus identifying the ‘individual spectral signature’ of each 
chromagen, saving and unmixing it from adjacent colours. Once unmixed the images 
are re-coloured to enable distinction of chromogens and inversion to a pseudo-
fluorescence image (Figure S7). In addition, confocal examination of double epitope 
fluorescent immunostains was performed to confirm MERTK expression in 
macrophages and to overcome a few obstacles such as the thickness of the 
histological sections, which allowed for the overlapping of signals and the presence 
of intracellular pigments difficult to distinguish from the DAB visualized signal. 
H. Angiopoietin-2 enzymatic immunohistochemistry  
Explanted liver tissue was obtained in 6 patients undergoing orthotopic liver 
transplantation (OLT) due to cirrhosis, and 5 undergoing the same procedure for 
ACLF. Hepatic resection margins of colorectal malignancies (4 cases) served as 
normal control tissue. Tissue samples were taken for diagnostic histological 
examination and were formalin-fixed and paraffin-embedded. Angiopoietin-2 (Ang-2) 
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expression was assessed using the ImageJ software (Bethesda, Maryland, USA) on 
10 random high power fields (HPF) from portal tracts in the control group and fibrous 
septa in the cirrhosis and ACLF groups, as well as from hepatic plates in all three 
groups. Immunostains were analyzed by a liver histopathologist (A.Q.) who was 
blinded to clinical data. 
FFPE tissue was cut at 4?m using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-l-lysine coated slides which were manually 
stained using a mouse monoclonal anti-Ang-2 primary antibody (catalog number sc-
74403, Santa Cruz Biotechnology, Germany; dilution 1:50). Slides were dewaxed in 
xylene, rehydrated, subjected to heat-induced epitope retrieval (HIER) using Tris-
EDTA, pH 9, for 20 minutes, and allowed to cool, followed by 1h incubation at room 
temperature with the primary antibody. The signal was detected using the Novolink 
Polymer Detection kit (code RE7200-K, Novocastra, Newcastle, UK), and visualized 
with 3,3’-diaminobenzidine (DAB) (code 4065, Dako, Cambridgeshire, UK). The 
slides were then dehydrated with alcohol, cleared with xylene and cover slipped with 
DPX (Leica Biosystems, UK) after hematoxylin counterstaining. Sections were 
imaged with a Leica DM6000 B microscope (Leica Biosystems, Newcastle, UK) 
equipped with a Leica DFC300 FX camera (Leica Biosystems, Newcastle, UK). 
Images were captured and archived using the Leica Laser Microdisection LMD 
software, version 6.7.0.3754 (Leica Biosystems, Newcastle, UK). 
Random HPF (400 ×) were selected as follows: 10 HPF containing portal tracts and 
10 HPF from hepatic plates in the control group; 10 HPF from fibrous septa and 10 
HPF from hepatic plates in the Cirrhosis and ACLF groups. After software calibration 
using a grid embedded in the image, the regions of interest (ROI) from each image 
were selected as follows: portal tracts and fibrous septa within each HPF. Their 
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areas were measured using the Freehand Selection tool and the Measure command 
from the Analyze menu. In the case of HPF from hepatic plates, the area of the 
entire HPF was measured using the same tools. Tissue areas outside the ROIs were 
excluded using the Clear Outside tool from the Control Panel menu. Images were 
then converted to RGB stacks (Image?Type?RGB Stack) and the Blue channel 
was selected for signal analysis. After adjusting the threshold 
(Image?Adjust?Threshold), the area of the Ang-2 signal was assessed using the 
Measure command. Results were expressed as percentage of Ang-2 signal within 
the ROI. 
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Table S1 
Parameter Cirrhosis   Acute ACLF ALF 
Child A-C 
(n=17) 
Child A 
(n=7) 
Child B/C 
(n=10) 
(AD) 
(n=9) (n=41) (n=23) 
       
Age (years) 55 (47-63) 60 (55-67) 52 (36-60) 50 (42-64) 48 (37-57) 35 (26-47) 
       
Child-Pugh 8 (6-9) 6 (6-6) 9 (8-10) 11 (10-13) 12 (11-13) ‡§ 13 (11-13)  
MELD 11 (8-16) 9 (7-11) 16 (11-17) 17 (14-29) 33 (25-39) ‡§ 38 (33-40) 
CLIF-SOFA 3 (1.5-5) 3 (0-3) 4.5 (3-5) 8 (7-10) 14 (12-17) ‡§ - 
NACSELD 0 0 0 0 2 (1-3) ‡§ - 
       
SOFA NA NA NA 10.5 (8.3-12.8)* 13 (11.3-14.8) 12 (8-15) 
APACHE II NA NA NA 20 (16.8-22.5)* 23 (19-26) 19 (11-24) 
SAPS II NA NA NA 28 (22.3-32.3)* 36 (27.3-43-5) 37 (24-48) 
       
Bilirubin (?mol/l) 29 (16.5-72) 23 (11-28) 58 (25-98) 178 (39-309.5) 140 (83.5-328.5) ‡ 92 (53-193)  
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INR 1.3 (1.2-1.6) 1.3 (1.0-1.4) 1.4 (1.2-1.8) 2.1 (1.7-2.6) 2.0 (1.7-2.9) ‡ 4.57 (2.69-8.39)  
ASAT (U/l) 50 (31.5-99) 46 (25-55) 75 (32-159) 73 (47-461) 115 (72-298.5) ‡ 3255 (865-6674) 
       
Lactate (mmol/l) 1.8 (1.3-2.4) 1.6 (1.3-2.2) NA 1.7 (1.0-2.1) 1.8 (1.2-2.9) 2.9 (2.2-4.9) 
pH 7.39 (7.38-7.41) 7.38 (7.38-7.40) 7.43 (7.41-7.44) 7.44 (7.42-7.46) 7.40 (7.34-7.44) 7.41 (7.37-7.45) 
       
WBC  (x10e9/l) 4.8 (3.7-6.9) 4.5 (4.1-5.5) 5.7 (3.2-7.9) 6.5 (2.3-12.4) 11.1 (6.3-14.6) ‡ 10.53 (8.13-16.29)  
Monocytes (x10e9/l) 0.41 (0.27-0.52) 0.36 (0.25-0.46) 0.47 (0.25-0.62) 0.52 (0.18-0.86) 0.52 (0.33-0.86) ‡ 0.36 (0.17-0.73)  
CRP (mg/dl) 8.5 (3.8-27.0) 5.5 (2.5-9.2) 35.8 (18.1-53.7) 20.2 (9.3-94.1) 52.2 (33.7-78.3) ‡ 17.1 (4.5-41.1)  
SIRS score 0 (0-1) 0 (0-1) 0 (0-1) 1 (1-1.5) 2 (1-2) ‡ 2 (1-3)  
       
Variceal bleed at 
admission n (%) 
0 (0%) - - 2 (22.2%) 16 (39.0%) 0 (0%) 
Suspected infection at 
admission n (%) 
0 (0%) - - 3 (33.3%) 13 (31.7%) 1 (4.4%) 
Culture positive infection 
at admission n (%) 
0 (0%) - - 2 (22.2%) 3 (7.3%) 2 (8.7%) 
Secondary infectious 
complications n (%) 
0 (0%) - - 1 (11.1%) 14 (34.1%) 5 (21.7%) 
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Corticosteroid treatment 
at admission n (%) 
0 (0%) - - 1 (11.1%)** 17 (41.5%)*** 4 (17.4%)*** 
Antibiotic treatment at 
admission n (%) 
0 (0%) - - 8 (88.8%) 37 (90.2%) 22 (95.7%) 
Table S1. Disease severity scores and clinical parameters and characteristics for the different groups of patients with 
cirrhosis and ACLF. Clinical characteristics and calculated disease severity scores for the different groups of patients at the time 
of blood sampling and experimental ex-vivo assays. Data are expressed as medians (IQR). Differences were calculated using 
Mann-Whitney tests. Culture positive infectious complications at admission and with 14 days after admission (secondary infections) 
for AD or ACLF. Data are expressed as number and % of patients. Cause for ACLF: infection (n=13[32%]; gastrointestinal bleeding 
n=16[39%]; other n=4[10%]; unknown n=8[20%]; Cause for AD: infection n=3[33%]; gastrointestinal bleeding n=2[22%]; other 
n=3[33%]; unknown n=1[11%];  
NA, not applicable/available. Ns, not statistically significant (p?0.05). ‡ significant difference comparing patients with ACLF to 
cirrhosis (Child-Pugh A-C); § significant difference comparing patients with ACLF to acute decompensated patients (AD); * 
applicable for AD patients admitted to intensive care only; ** for autoimmune hepatitis; *** for autoimmune disease or suspected 
relative adrenal insufficiency; 
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ACLF, acute on chronic liver failure; MELD, model of end-stage liver disease; SOFA, Sequential Organ Failure Assessment score; 
CLIF, Consortium on Chronic Liver Failure; APACHE II, Acute Physiology and Chronic Health Evaluation II; SAPS II, Simplified 
Acute Physiology Score II; NACSELD, North American Consortium for Study of End-stage Liver Disease; INR, international 
normalised ratio; ASAT, aspartate aminotransaminase; WBC, white blood cells; CRP C-reactive protein; SIRS, Systemic 
inflammatory response syndrome. 
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Supplementary Figure Legends 
Figure S1. MERTK expressing macrophages accumulate in the liver and in 
mesenteric lymph nodes but not the bone marrow in patients with ACLF and 
decompensated cirrhosis. A. Representative confocal images of double-epitope 
fluorescent immunostaining for CD68(green)/MERTK(red)/co-localization(yellow) in 
explanted liver tissue from control- (upper panel) and cirrhosis patients (lower panel), 
and follicular areas of regional lymph nodes from control (upper panel) and 
decompensated cirrhosis (lower panel) (400× magnification). B. Representative 
single-epitope immunostaining for MERTK (purple) in bone marrow tissue from a 
decompensated cirrhotic patient (upper left panel); representative composite 
pseudofluorescent images of MERTK-Ki67 double-epitope immunostaining in liver 
tissue from control (upper right), cirrhosis (lower left) and ACLF patients (lower right) 
(200×). C. Representative micrographs of double-epitope fluorescent staining for 
MERTK-Ki67 in non-follicular areas of lymph nodes from control- and 
decompensated cirrhotic patients (400×). D. Representative example of Nuance 
multispectral imaging used to determine MERTK/CD163 co-localisation in ACLF 
explanted liver tissue: double-epitope immunostaining demonstrating 
MERTK+(brown)/CD163+(purple) cells (200×); pseudofluorescent image of 
MERTK+(green), CD163+(red) cells following the unmixing process and co-
localisation (yellow). 
Figure S2. Representative FACS plot for ex-vivo MERTK staining on 
monocytes in fresh whole blood. Whole blood from a healthy control compared to 
an ACLF patient was stained within 2 hours of sampling to assess monocyte MERTK 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MERTK in ACLF – Supplementary Figure Legends   
2
expression by flow-cytometry. Monocytes in ACLF were predominantly CD14+ 
(>95%) and MERTK expression was highest in the CD14+CD16+ monocyte 
population.  
Figure S3. MERTK expression on monocytes, Gas-6- and Galectin-3 levels in 
ACLF do not differ between aetiologies of chronic liver disease. A. MERTK 
expression on monocytes assessed by flow-cytometry is expressed as mean 
fluorescence intensity (MFI). B. Gas-6 levels (pg/ml) and C. Galectin-3 levels (ng/ml) 
were assessed by ELISA. Values were separated by aetiology of liver disease. ACLF 
patients (n=41): alcoholic liver disease (ALD) (n=19), non-alcoholic fatty liver disease 
(NAFLD) (n=6), hepatitis C virus infection (HCV) (n=1), autoimmune hepatitis (AIH) 
(n=3), cholestatic liver disease (n=2), alpha1-antitrypsin deficiency (A1AT) (n=3), 
and rare diseases such as hereditary haemochromatosis (HHC) (n=1), Wilson’s 
disease (n=1), nodular regenerative hyperplasia (NRH) (n=1), Alagille’s syndrome 
(n=1), chronic Budd-Chiari (n=1), cryptogenic cirrhosis (n=1). Graphs show 
median/IQR if applicable. Differences between groups of disease of n?2 were 
calculated by Mann-Whitney tests; there were no significant differences detected. 
Figure S4. MERTK expression is related to SIRS response and liver disease 
severity.  A. MERTK expression on monocytes (MFI) in ACLF/AD patients with no 
SIRS (SIRS score 0-1) vs. SIRS (SIRS score 2-4). B. MERTK expression in patients 
with no SIRS and SIRS with and without culture positive infection (no SIRS – no 
infection n=22; no SIRS – infection n=7; SIRS – no infection n=9; SIRS – infection 
n=9). C. MERTK expression in relation to the aetiology of decompensation. D. 
MERTK expression on monocytes in correlation to the leucocyte count (x10e9/l) and 
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plasma CRP level (mg/l). E. MERTK expression in relation to antibiotic treatment at 
baseline (n=3 without antibiotics; n=37 on broad spectrum antibiotics). F. Steroid 
treatment at admission in relation to liver disease severity scores MELD, CLIF-SOFA 
and MERTK expression (without steroids [w/o] n=23; on steroid treatment for 
autoimmune disease or clinically suspected relative adrenal insufficiency n=17). 
Mann-Whitney tests. 
Figure S5. Bacterial killing is preserved in acute on chronic liver failure.
Monocyte intracellular killing of E.coli by oxidative burst was investigated ex-vivo in 
whole blood samples. A. Representative FACS plot showing oxidative burst activity 
(% CD14+ cells) in a healthy control and a patient with ACLF. B. Monocyte oxidative 
burst in patients with ACLF (n=34) and cirrhosis (n=11) and compared to healthy 
controls (n=23). C. Oxidative burst activity in patients with ACLF and different 
outcome: 28-day survival (good; n=12), patients undergoing OLT within 28 days 
(n=5) and non-survivors (n=17). D. Ex-vivo oxidative burst activity in ACLF patients 
followed over 14 days after admission (BL, baseline, day 3-5, day 7-10, day 14). E. 
Fc?-receptor expression (CD64, CD32) on monocytes from ACLF patients and 
healthy controls ex-vivo (n=9 each). F. Oxidative burst in response to E.coli after 
conditioning of healthy monocytes in ACLF- compared to healthy plasma in-vitro (% 
CD14+ cells) (left) and oxidative burst in response to E.coli after treatment with 
UNC569 (2μM) for 2h (n=4 each; right). 
Figure S6. Systemic cytokine levels in ACLF patients. A-G. A panel of different 
cytokines was measured in the plasma of patients with ACLF (n=43) compared to 
stable cirrhosis (n=17) and healthy controls (n=20). TNF-? (A), IL-6 (B), IL-10 (C), IL-
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8 (D), IFN-? (E), TGF-?1 (F), IL-1? (G), IL-12 (H). Data are expressed as pg/ml and 
represented as box-plots. Differences were calculated using Mann-Whitney tests.  
Figure S7. Healthy monocytes cultured in ACLF plasma differentiate towards a 
MERTK expressing, immunomodulatory population. Healthy monocytes were 
cultured in medium containing ACLF plasma from different donors (n=10) compared 
to healthy plasma (n=2) for 36h. Differential expression of cell surface markers after 
conditioning in different plasma was assessed by flow-cytometry: MERTK, CD16, 
HLA-DR, CD86, CD163, CD64, CD32, CX3CR1, CCR5, CCR7. Data are expressed 
as MFI. Graphs show median/IQR.
Figure S8. Inhibition of pro-inflammatory cytokine production in response to 
LPS-challenge in monocytes cultured in ACLF plasma. Healthy monocytes 
conditioned with ACLF plasma for 36h were stimulated with LPS (100ng/ml) and 
TNF-? (A) and IL-6 (B) secretion were measured in cell culture supernatants by 
ELISA. Levels are expressed in pg/ml of media. 
Figure S9. MERTK expression in relation to coagulation and markers of 
endothelial activation.  A. MERTK expression on monocytes in CLD (MFI) is 
positively correlated to INR but not platelets. B. Markers of endothelial activation 
(human soluble intercellular adhesion molecule-1 (hs ICAM-1; ng/ml) and human 
soluble vascular cell adhesion molecule 1 (hs VCAM-1; ng/ml) are elevated in 
patients with cirrhosis (n=8) and ACLF (n=24) compared to healthy controls (n=8). 
MERTK expression on monocytes did correlate with neither hs ICAM-1 (Spearman 
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r=0.200; ns) nor hs VCAM-1 (r=-0.079; ns). C. Representative single epitope 
immunohistochemistry for Angiopoitin-2 (Ang-2) in cases from the control, cirrhosis 
and ACLF groups (100× magnification) showing little expression in sinusoids in all 
groups, and increased endothelial expression in vessels from fibrous septa in 
cirrhosis and ACLF compared to the controls. Percentage of Ang-2 signal within 
regions of interest in all three groups (Control n=4; cirrhosis n=6, ACLF n=5). 
Figure S10. Phenotypic differentiation of peritoneal macrophages in 
comparison with circulatory monocyte ex-vivo. Paired samples of peripheral 
blood and ascites were obtained from n=5 patient with cirrhosis complicated by 
ascites. Cell surface marker expression of HLA-DR, CD163, CD64, CX3CR1, CCR5, 
and CCR7 was assessed by flow-cytometry and compared between circulatory 
monocytes and peritoneal macrophages (pM?). Data are expressed as MFI and 
represented as box-plots.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
?
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
monocytes p Mφ
0
10000
20000
30000
40000
50000
M
FI
**
monocytes p Mφ
0
2000
4000
6000
8000
M
FI
**
monocytes p Mφ
0
500
1000
1500
2000
2500
M
FI
*
monocytes p Mφ
0
2000
4000
6000
8000
10000
M
FI
*
HLA-DR CD163 CCR7CX3CR1
monocytes p Mφ
0
5000
10000
15000
M
FI
*
monocytes p Mφ
0
2000
4000
6000
8000
10000
M
FI
*
CCR5CD64
